This Procedural Bulletin is intended to provide a ready outline reference for performance of the assay. These abbreviated directions for use are not intended to replace the complete package insert. It is the obligation of every manufacturer of medical devices labeled FOR IN VITRO DIAGNOSTIC USE to provide a complete package insert in accordance with FDA labeling regulation (21 CFR 809.10). Prepared in accordance with the guidelines recommended by the Clinical and Laboratory Standards Institute, Wayne, PA 19087; CLSI Document GP2-A2.

Quidel Corporation provides CLSI procedures for your use. The procedures are required to include the same information as listed in the package insert. Any modifications to this document are the sole responsibility of the Laboratory.
INTENDED USE
QuickVue+ Infectious Mononucleosis test is a rapid Color ImmunoChromatographic Assay (CICA) for the detection of Infectious Mononucleosis IgM heterophile antibodies in serum, plasma or whole blood. This test is intended for use as an aid in the diagnosis of Infectious Mononucleosis. For use by healthcare professionals.

SUMMARY AND EXPLANATION
Infectious Mononucleosis (IM) is usually a self-limiting disease that is caused by the Epstein-Barr Virus (EBV).\textsuperscript{1,2} The most common symptoms are fatigue, pharyngitis, fever, lymphadenopathy, splenomegaly and hepatitis.\textsuperscript{3} In rare cases, complications may develop including severe thrombocytopenia, hemolytic anemia, pericarditis, myocarditis, pneumonitis, Reye’s syndrome, encephalitis and other neurological syndromes. In industrialized countries, the peak incidence of IM occurs between 14 and 18 years of age. In developing or densely populated countries, most children become infected before 3 years of age and symptoms may be mild or clinically inapparent.\textsuperscript{4,5}

During the acute phase of illness, certain heterophile antibodies appear in 85–90% of IM cases. These antibodies, known as IM heterophile antibodies, are primarily of the IgM class.\textsuperscript{6,7} IgM to the viral capsid antigen appears early in infection and disappears within 4 to 6 weeks. IgG to the viral capsid antigen appears in the acute phase, peaks at 2 to 4 weeks after onset, declines slightly, and then persists for life.\textsuperscript{8} Although the exact mechanism leading to IM heterophile antibody expression has not been determined, the antibodies are specifically associated with the disease. The IM heterophile antibodies are usually demonstrable one week after the onset of illness, peak at two to four weeks, and decline to low levels by 12 weeks.\textsuperscript{2} Heterophile antibodies have been detected in patients’ serum over one year after the onset of illness.\textsuperscript{9}

Reliable laboratory diagnosis of IM has been performed for over fifty years based on the detection of IM heterophile antibodies. These heterophile antibodies are directed against antigens found in bovine, sheep and horse erythrocytes (QuickVue+ Infectious Mononucleosis test utilizes an extract of bovine erythrocytes which gives a greater sensitivity and specificity than similar extracts prepared from sheep and horse erythrocytes).\textsuperscript{10,11} The Forssman antibody, which can interfere with some IM heterophile antibody assays,\textsuperscript{7} does not interfere with the QuickVue+ Infectious Mononucleosis test.
PRINCIPLE OF THE TEST
The QuickVue+ Infectious Mononucleosis test assay uses Color ImmunoChromatographic Assay (CICA) technology for the qualitative detection of human heterophile IM antibodies (IgM class) in serum, plasma or whole blood. The Reaction Unit consists of a plastic housing containing a membrane strip which provides the solid support for the immunochromatographic assay. The right end of the membrane provides contact with the sample well. The sample well contains an absorbent pad which provides an even flow of the sample fluid (from right to left) along the membrane. The first zone of the membrane (which is covered by the Reaction Unit label) is coated with blue latex beads that are conjugated to goat anti-human IgM antibodies (antibody-blue latex). Two agents are immobilized on the second zone of the membrane, which is exposed in the “Read Result” window. These agents include blue latex beads (non-conjugated) immobilized on the membrane to provide a pre-printed blue horizontal line. The second agent is a bovine erythrocyte extract, which is immobilized on the vertical line. The third zone of the membrane (exposed in the “Test Complete” window) contains an agent capable of binding the antibody blue latex to provide the vertical “Test Complete” line. An absorbent pad is situated at the left end of the membrane to retain fluid after the reaction is completed. A drying agent is enclosed in the Reaction Unit to stabilize the reactive agents.

In the Test Procedure, serum, plasma or whole blood is added to the “Add” well, followed by the addition of the Developer. As the sample/developer fluid moves by capillary action across the first zone of the membrane, it mobilizes the antibody-blue latex. The fluid continues to move the antibody-blue latex across the membrane to the immobilized bovine erythrocyte extract (antigen) zone. If the specific IM heterophile antibodies are present in the sample, a “sandwich” of solid phase/IM antibody/antibody-blue latex is formed. The vertical line will appear resulting in a positive sign (+) visible in the “Read Result” window, which indicates the presence of IM heterophile antibody. If the antibody is not detected, the “Read Result” window will only contain the preprinted blue horizontal line, indicating a negative (–) result. As the fluid continues to move the antibody-blue latex across the membrane, it comes in contact with the reagent in the “Test Complete” window. A blue line will appear, indicating the test is complete.

REAGENTS AND MATERIALS PROVIDED
Each QuickVue+ Infectious Mononucleosis test kit contains enough reagents and materials for 20 tests.
1. Reaction Units (20): Test strip contains anti-human IgM and immobilized extracted bovine erythrocyte antigens.
2. Developer (5 mL): Detergent, 0.2% sodium azide.
3. Mono Negative Control (1 mL): Normal human serum diluted in saline solution, 0.2% sodium azide.
4. Mono Positive Control (1 mL): IgM heterophile antibody positive human plasma diluted in saline solution, 0.2% sodium azide.

5. Sample Pipettes (20)

6. Capillary Tubes (20)

7. Package Insert (1)

8. Procedure Card (1)

MATERIALS REQUIRED BUT NOT PROVIDED
1. Vacutainer tubes: EDTA, heparin, or citrate for plasma and venipuncture whole blood procedure.

2. Finger Lancet for fingertip blood procedure.

3. Centrifuge.

WARNINGS AND PRECAUTIONS
■ For in vitro diagnostic use.

■ DO NOT use after expiration date. DO NOT mix components from different lots or different kits.

■ Use appropriate precautions in the collection, storage, handling and disposal of patient samples and used kit contents.

■ Use of Nitrile or Latex gloves is recommended when handling patient samples.¹²

■ Dispose of containers and unused contents in accordance with Federal, State, and Local requirements.

■ DO NOT interchange caps among reagents.

■ Warning: Potential Biohazardous Material
   Each donor unit of human serum or plasma used in the preparation of the Positive and Negative Controls was tested by an FDA-licensed method for the presence of the antibody to human immunodeficiency virus type HIV-1/HIV-2, as well as hepatitis B surface antigen (HBsAg) and anti-HCV, and found to be negative. Nevertheless, caution should be used in handling and disposing of these items at biosafety level 2,
as recommended in the Centers for Disease Control/National Institutes of Health Manual, Biosafety in Microbiological and Biomedical Laboratories, 2007.

To obtain accurate results, you must follow the Package Insert instructions.

KIT STORAGE AND STABILITY
Store kit at room temperature 59–86°F (15–30°C), out of direct sunlight. Kit contents are stable until the expiration date printed on the outer box. Do not freeze.

SAMPLE COLLECTION AND STORAGE
1. Serum, plasma or whole blood (including fingertip blood) can be used. Specimens must be collected in a manner appropriate for laboratory testing.

2. Whole blood containing EDTA, heparin, or citrate as an anti-coagulant may be used immediately without centrifugation; or may be stored at 2–8°C for up to 72 hours.

3. Fingertip blood should be tested immediately after the sample is taken.

4. Plasma samples containing EDTA, heparin, or citrate as an anti-coagulant can be used.

5. Serum or plasma samples can be stored at 2–8°C for up to 72 hours, or below -20°C (-4°F) for three months. Samples should not be repeatedly frozen and thawed. Thawed samples should be inverted several times just prior to testing.

6. Whole blood samples in which cell lysis has occurred will cause a red background to appear in the “Read Result” window. However, the result remains valid.

Recommendations for Whole Blood Fingertip Sampling:
- Wash patient’s hand with soap and warm water or clean with an alcohol swab. Allow to dry.
- Massage the hand without touching puncture site by rubbing down the hand and finger towards the tip.
- The side of the middle or ring finger is the preferred puncture site.
- Puncture the skin with the lancet. Wipe away first sign of blood.
- Gently rub the hand from wrist to palm to finger in order to form a rounded drop of blood over the puncture site. Avoid squeezing around the puncture site.
For Hanging Drop Sampling: position the finger so that the drops of blood are just above the center of the “Add” well of the Reaction Unit.

For Capillary Tube Sampling: touch the capillary tube to the blood until filled.

QUALITY CONTROL

External Quality Control
External controls may also be used to demonstrate that the reagents and assay procedure perform properly.

Quidel recommends that positive and negative controls be run once for each untrained operator, once for each new shipment of kits — provided that each different lot received in the shipment is tested — and as deemed additionally necessary by your internal quality control procedures, and in accordance with local, state, and federal regulations or accreditation requirements.

External Positive and Negative Controls are provided in the kit.

External Positive Control: Put one drop of Positive Control in the “Add” well. Put five drops of Developer in the “Add” well. Process the control as you would a patient sample. A positive signal is indicated by a vertical blue line in the “Read Result” window, resulting in a positive sign (+).

External Negative Control: Put one drop of Negative Control in the “Add” well. Put five drops of Developer in the “Add” well. Process the control as you would a patient sample. A negative signal is indicated by a horizontal blue line (–), in the “Read Result” window.

Internal Quality Control

Internal Positive Procedural Control: A blue line in the “Test Complete” window is considered an internal positive procedural control. If the test has been performed correctly and the Reaction Unit is working properly, this indicator will appear. If no blue color is visible in the “Test Complete” window after 10 minutes, the test result is invalid.

Internal Negative Procedural Control: A clear background in the “Read Result” window is also considered an internal negative procedural control. If the test has been performed correctly and the Reaction Unit is working properly, the background will clear to give a discernible result.

Procedural Notes
1. DO NOT open the foil pouch until you are ready to perform the test.

2. Several tests may be run at one time.
3. To avoid cross-contamination, use a new disposable Sample Pipette for each sample.

4. To avoid contamination, do not touch the tip of the Developer bottle to the Reaction Unit.

5. Commercial controls other than Quidel’s should not be used with QuickVue+ Infectious Mononucleosis test because they may contain additives which will interfere with the test performance.

TEST PROCEDURE - SERUM, PLASMA, WHOLE BLOOD

Read all of the procedural instructions before running patient samples.

Remove the Reaction Unit from the pouch and place it on a well-lit and level surface.

The “Read Result” window contains a horizontal blue line pre-printed on the membrane.
Hanging Drop Procedure
Add two (2) hanging drops of fingertip blood directly to the center of the “Add” Well.

OR

Capillary Tube Procedure
For fingertip blood, fill the capillary tube (50 µL) to line. Dispense all blood into the “Add” well.

OR

Venipuncture, Serum or Plasma Procedure
For serum, plasma or whole blood samples in tubes, use the sample pipette provided. Place one drop of sample in the “Add” well.

When adding drops, hold the Developer bottle vertically so that a Complete drop forms. Add 5 drops of Developer to the “Add” well.

Read test result when ANY blue color appears in the Test Complete window (approximately 5 minutes).

Do not read test result after 10 minutes.

Refer to Interpretation of Results section for further information.
INTERPRETATION OF RESULTS
FOR PATIENT SAMPLES, POSITIVE AND NEGATIVE CONTROLS

Positive Result:
Any shade of a blue vertical line forming a (+) sign in the “Read Result” window along with the blue “Test Complete” line, is a positive result. **Even a faint blue vertical line should be reported as a positive.**

Negative Result:
No blue vertical line in the “Read Result” window along with the blue “Test Complete” line, is a negative result.

Invalid Result:
Test result is invalid if after 10 minutes no blue color is observed in the “Test Complete” window.

An invalid result indicates either the test was not performed correctly or the reagents are not working properly.

Should an invalid result occur, re-test the sample using a new Reaction Unit.

If the problem continues, contact Technical Support toll-free in the U.S. at (800) 874-1517. Outside the USA, contact your local representative.
LIMITATIONS
1. As is the case of any other diagnostic procedure, the results obtained by this kit yield data that must be used in addition to other information available to the physician.

2. QuickVue+ Infectious Mononucleosis test is a qualitative test for the detection of IM heterophile antibodies.

3. A negative result may be obtained from patients at the onset of the disease due to antibody concentration below the sensitivity of this test kit. If symptoms persist or increase in intensity, the test should be repeated.

4. Some segments of the population who contract Infectious Mononucleosis do not produce measurable levels of heterophile antibodies. Approximately 50% of children under 4 years of age who have IM may test as IM heterophile antibody negative.4

PERFORMANCE CHARACTERISTICS
QuickVue+ Infectious Mononucleosis test was compared to two other commercially available test kits: an EIA, and a slide hemagglutination test. The results obtained using QuickVue+ Infectious Mononucleosis test were substantially equivalent to the results obtained using these other tests and are summarized below.

**Table 1:** In this study, a total of 511 serum, plasma and whole blood samples were tested using QuickVue+ Infectious Mononucleosis test and a commercially available EIA.

<table>
<thead>
<tr>
<th></th>
<th>EIA Positive</th>
<th>EIA Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QuickVue+ IM Positive</strong></td>
<td>74</td>
<td>1</td>
</tr>
<tr>
<td><strong>QuickVue+ IM Negative</strong></td>
<td>0</td>
<td>436</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>74</td>
<td>437</td>
</tr>
</tbody>
</table>

Of the 511 samples, 74 were found to be positive by EIA and also positive by the QuickVue+ Infectious Mononucleosis test; similarly, 437 were found to be negative by EIA and 436 were also negative by the QuickVue+ Infectious Mononucleosis test.

Based on this data, **specificity was 99.8%** (436/437), and **sensitivity was >99.9%** (74/74). **Overall agreement was 99.8%** (510/511).
Table 2: In this study, a total of 511 serum, plasma and whole blood samples were tested using QuickVue+ Infectious Mononucleosis test and a commercially available slide hemagglutination test.

<table>
<thead>
<tr>
<th></th>
<th>Slide Positive</th>
<th>Slide Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>QuickVue+ IM Positive</td>
<td>74</td>
<td>1</td>
</tr>
<tr>
<td>QuickVue+ IM Negative</td>
<td>1</td>
<td>435</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>75</strong></td>
<td><strong>436</strong></td>
</tr>
</tbody>
</table>

Of the 511 samples, 75 were found to be positive by the slide hemagglutination test and 74 were also positive by the QuickVue+ Infectious Mononucleosis test; similarly, 436 were found to be negative by the slide hemagglutination test and 435 were also negative by the QuickVue+ Infectious Mononucleosis test.

Based on this data, **specificity was 99.8%** (435/436), and **sensitivity was 98.7%** (74/75). **Overall agreement was 99.6%** (509/511).

ASSISTANCE

If you have any questions regarding the use of this product, please call Quidel's Technical Support Number (800) 874-1517 (toll-free in the U.S.A.) or (858) 552-1100, Monday through Friday, between 7:00 a.m. and 5:00 p.m., Pacific Time, U.S.A. If outside the United States, contact your local distributor or technicalsupport@quidel.com.

REFERENCES


Covered by U.S. Patent No. 5,763,262.

20121 – QuickVue+ Infectious Mononucleosis 20 Test Kit

MDSS GmbH
Schiffgraben 41
30175 Hannover,
Germany

Quidel Corporation
Worldwide Headquarters
10165 McKellar Court
San Diego, CA 92121 USA
[www.quidel.com](http://www.quidel.com)
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC REP</td>
<td>Authorized Representative in the European Community</td>
</tr>
<tr>
<td>REF</td>
<td>Catalog number</td>
</tr>
<tr>
<td>CONTROL+</td>
<td>Positive control</td>
</tr>
<tr>
<td>CONTROL−</td>
<td>Negative control</td>
</tr>
<tr>
<td>Use by</td>
<td>Consult instructions for use</td>
</tr>
<tr>
<td>LOT</td>
<td>Batch code</td>
</tr>
<tr>
<td>IVD</td>
<td>For In Vitro diagnostic use</td>
</tr>
<tr>
<td>Manufacturer</td>
<td></td>
</tr>
<tr>
<td>Temperature limitation</td>
<td></td>
</tr>
</tbody>
</table>
## LOG SHEET

*Record Built-in Procedural Controls on the first patient tested each day.*

<table>
<thead>
<tr>
<th>Date</th>
<th>Patient Name</th>
<th>Negative Procedural Control (Clear Bkgd)</th>
<th>Positive Procedural Control (Blue Line)</th>
<th>Test Results At 5 minutes</th>
<th>Lot Number and Exp. Date</th>
<th>Technician</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**LOG SHEET**

*Need to run external Positive and Negative controls once for each untrained operator, once for each new shipment of kits – provided that each different lot received in the shipment is tested – and as deemed additionally necessary by your internal quality control procedures, and in accordance with local, state, and federal regulations or accreditation requirements.*

<table>
<thead>
<tr>
<th>Date/Date Received</th>
<th>External Positive Control</th>
<th>External Negative Control</th>
<th>Lot Number and Exp. Date</th>
<th>Technician</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Catalog Number: 20121 (20-Test kit)  Page 15 of 15